The Role of Extracellular Vesicles in Chronic Inflammatory and Immune Processes
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (20 August 2022) | Viewed by 8228
Special Issue Editor
Special Issue Information
Dear Colleagues,
Extracellular vesicles (EVs) comprise several classes of cell-derived nanoparticles secreted or passively shed by cells. EVs are evolutionarily conserved and play central roles in cellular communication. As such, mounting evidence points to their utility not only as diagnostic and prognostic markers of disease but also as therapy. Indeed the mechanism of action of many cell therapies relies on the secretion of EVs to mediate these effects. A central function of EV therapy revolves around their immunomodulatory bioactivity including attenuating the innate and adaptive immune response.
Several studies in cell therapy models implicate EV cargo including small non-coding RNAs in regulating the expression of pro-inflammatory mediators. Moreover, chronic inflammation is the main driver behind diseases including heart failure, pulmonary fibrosis, and autoimmune disease. The capacity of EV-related cargo to modulate the transcriptome and epigenome of target cells rationalizes their capacity to attenuate chronic inflammation.
The focus of this special issue is the mechanism by which EVs and their constituents disrupt chronic inflammation in a variety of disease contexts. Chronic inflammation comprises the inflammasome pathway, innate immune, and adaptive immune activation.
Dr. Ahmed Ibrahim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- extracellular vesicles
- exosomes
- chronic inflammation
- adaptive immunity
- innate immunity
- immunomodulation
- anti-inflammation
- microRNAs
- chronic inflammation
- inflammasome
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
